Clomipramine in Obsessive-Compulsive Disorder

Benkelfat, Chawki

doi:10.1001/archpsyc.1989.01810010025004

Cited by 133 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The remaining nine studies were excluded because the authors did not respond to our request to provide the relevant data (Benkelfat et al, 1989; Fals-Stewart, Marks, & Schafer, 1993; Goodman, Kozak, Liebowitz, & White, 1996; Goodman et al, 1989; Hiss, Foa, & Kozak, 1994; Katz, DeVeaugh-Geiss, & Landau, 1990; Leonard et al, 1991; March et al, 1998; Stein, Hollander, Mullen, DeCaria, & Liebowitz, 1992). …”

Section: Resultsmentioning

confidence: 99%

Minority Participation in Randomized Controlled Trials for Obsessive-Compulsive Disorder

Williams

Powers²,

Yun

et al. 2010

Journal of Anxiety Disorders

122

View full text Add to dashboard Cite

This paper reviews published randomized trials in North America to determine whether minority groups are underrepresented in clinical trials of OCD. A search of the literature produced 40 randomized trials of both adults and children with OCD, conducted in the U.S. and Canada from 1989 to 2009 (N = 3777). The groups included in this review were Caucasians/European Americans, Black/African-Americans, Hispanic/Latino-Americans, Asian-Americans, Others, and Unknown. Of these, 22 of 40 trials reported ethnic/racial information or data was available by request. We focused on the 21 trials from 1995 to 2008 providing ethnic/racial information, and among those (N = 2221), 91.5% of participants were Caucasian, 1.3% were African-American, 1.0% were Hispanic, 1.6% were Asian, 1.5% were Other, and 3.1% were Unknown. We conclude that minorities are underrepresented in North American OCD trials. Therefore, it is not known if empirically validated treatments are effective for these groups. Recommendations for improving recruitment of minorities for future studies are discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

Minority Participation in Randomized Controlled Trials for Obsessive-Compulsive Disorder

Williams

Powers²,

Yun

et al. 2010

Journal of Anxiety Disorders

122

View full text Add to dashboard Cite

show abstract

“…There is evidence that drugs with non-selective 5-HT receptor antagonist activities (e.g. metergoline) may be 'pro-obsessional drugs' and worsen OCD (Benkelfat et al, 1989). Interestingly, clozapine, which is also a non-selective 5-HT receptor antagonist may also worsen OCB in schizophrenia .…”

Section: Discussionmentioning

confidence: 99%

Risperidone in the treatment of Tourette syndrome: a retrospective case note study

et al. 1996

View full text Add to dashboard Cite

Nineteen patients with Tourette syndrome (TS) were treated with risperidone, at a mean daily dose of 1.5 mg. Of those, 41% responded positively, 35% felt that it had made no difference, while it made 24% worse. Although 53% of the patients experienced side-effects, none had extrapyramidal side-effects. At follow-up, 8 to 11 months later, only two of 19 (11 %) patients were still taking risperidone. We suggest that risperidone does have a role in a minority of TS sufferers but it is not suggested as the first line treatment. More placebo-controlled studies using risperidone are clearly indicated.

show abstract

“…Cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) have, in separate multicenter trials, demonstrated efficacy and tolerability in the treatment of 40–60% of OCD patients 1 , 2 . The success of SSRIs, relative to medications targeting neurotransmitter systems other than serotonin (5-hydroxytryptamine (5-HT)), suggests that the latter may play a role in the remediation of OCD symptoms 3 , 4 . Despite the documented effectiveness of these treatments, changes in neurochemistry in vivo associated with CBT or SSRI in OCD patients, including changes in the serotonergic system, remain elusive .…”

Section: Introductionmentioning

confidence: 99%

Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline

et al. 2018

Self Cite

View full text Add to dashboard Cite

Cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) are both effective treatments for some patients with obsessive-compulsive disorder (OCD), yet little is known about the neurochemical changes related to these treatment modalities. Here, we used positron emission tomography and the α-[11C]methyl-l-tryptophan tracer to examine the changes in brain regional serotonin synthesis capacity in OCD patients following treatment with CBT or SSRI treatment. Sixteen medication-free OCD patients were randomly assigned to 12 weeks of either CBT or sertraline treatment. Pre-to-post treatment changes in the α-[11C]methyl-l-tryptophan brain trapping constant, K* (ml/g/min), were assessed as a function of symptom response, and correlations with symptom improvement were examined. Responders/partial responders to treatment did not show significant changes in relative regional tracer uptake; rather, in responders/partial responders, 12 weeks of treatment led to serotonin synthesis capacity increases that were brain-wide. Irrespective of treatment modality, baseline serotonin synthesis capacity in the raphe nuclei correlated positively with clinical improvement. These observations suggest that, for some patients, successful remediation of OCD symptoms might be associated with greater serotonergic tone.

show abstract

Clomipramine in Obsessive-Compulsive Disorder

Cited by 133 publications

References 33 publications

Minority Participation in Randomized Controlled Trials for Obsessive-Compulsive Disorder

Minority Participation in Randomized Controlled Trials for Obsessive-Compulsive Disorder

Risperidone in the treatment of Tourette syndrome: a retrospective case note study

Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline

Contact Info

Product

Resources

About